ARCHIVES

NCI Letter To Pittsburgh Details Deficiencies In NSABP Operations

This article is from The Cancer Letter archive.

Vol. 20 No. 14 | April 8, 1994

Download PDF Visit The Full Archive

Related Articles

Recombinant TSH Avoids Need To Stop Replacement Therapy

January 27, 2006

In Brief: Bogardus Heads ASTRO, Million President Elect; Woods Named Chief of NIC Contracts Review

October 27, 1989

Cancer Advocacy: Jay Hedlund Resigns As NPCC President

May 14, 1999

White House appoints NCI Director Andrew von Eschenbach acting FDA commissioner after Lester Crawford resigns.

September 30, 2005

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

September 26, 2014

ODAC Votes 10-0 In Favor Of Avastin For Recurrent Glioblastoma Multiforme

April 3, 2009